Lentiviral transduction is a popular delivery platform for applications such as CAR-T cell engineering or CRISPR-Cas9 gene editing, as it can transduce both dividing and non-dividing cells and ...

researchers are more frequently selecting lentiviral transduction because (1) it provides long-lasting gene expression, (2) it is compatible with knock-in, knock-out, and knock-down CRISPR ...

Presenting at Technology Networks’<i/> Cell and Gene Therapy 2025 Symposium, Dr. Andrew Mancini, senior corporate development ...

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

The authors confirm that telomeres in telomerase-positive cells terminate with 5'-ATC in a Pot1-dependent manner, and demonstrate that this principle holds true in telomerase-negative ALT cells as ...

CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday. The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share.

Details of the presentations: Poster Talk Title: ENaBL, a Novel Lentiviral Vector Platform for In Vivo Engineering of Therapeutic Anti-BCMA CAR T Cells, Shows Effective T Cell Transduction and ...

Lentiviral vectors (LVVs) have proven to be extremely versatile genetic delivery vehicles, gaining space as a gene transfer technology tool used both for cell and gene therapies. They are utilised ...

“It takes more than one event to create cancer,” noted Snook. “It would be really hard for a single lentiviral insertion event to take a normal T cell and turn it into a cancer T cell. That would be ...